Verona signs Chi­na deal for PhI­II COPD drug; Te­va con­tin­ues le­gal bat­tle with Eli Lil­ly, al­leg­ing new patent in­fringe­ments on mi­graine drug

Af­ter a Feb­ru­ary Phase II win put Verona’s bad mem­o­ries of a 2019 flop be­hind them, the com­pa­ny is now en­gag­ing in part­ner­ships to ship out the ex­per­i­men­tal drug should it con­tin­ue to pro­duce pos­i­tive re­sults in Phase III.

Verona is team­ing up with Nu­ance Phar­ma on a $219 mil­lion col­lab­o­ra­tion to com­mer­cial­ize en­sifen­trine in Chi­na, Macau Hong Kong and Tai­wan, the com­pa­nies an­nounced Thurs­day. The deal in­cludes $25 mil­lion in up­front cash and a $15 mil­lion eq­ui­ty stake in Nu­ance Biotech, the par­ent com­pa­ny of Nu­ance Phar­ma. Verona is el­i­gi­ble for up to $179 mil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.